



## **MEDIA RELEASE**

# **QT VASCULAR ENTERS INTO ASSET PURCHASE AND OPTION AGREEMENT WITH TELEFLEX**

- **Teleflex will acquire the Company's commercial coronary products and an option to purchase the drug coated Chocolate Heart™**

**SINGAPORE, 24 May 2018** – QT Vascular Ltd., (“**QT Vascular**”, and with its subsidiaries, the “**Company**”), announced today that it has entered into an asset purchase and option agreement (the “**APOA**”) with Teleflex Life Sciences Unlimited Company and Teleflex Incorporated (“**Teleflex**”). Under the APOA, Teleflex will acquire the non-drug coated product line and licenses with respect to intellectual property related to the Company's non-drug coated coronary products (including Chocolate XD® and Glider™). The APOA also provides Teleflex with an option (the “**Option**”) to purchase the drug coated coronary balloon catheter, referred to as Chocolate Heart™, currently under development by the Company.

“We are excited that Teleflex, one of the world's leading medical device companies, chose to acquire our coronary products and to obtain a license to our extensive coronary IP portfolio,” stated Eitan Konstantino, PhD, CEO of QT Vascular. “We will work closely with Teleflex's team to bring our pioneering drug coated coronary product, Chocolate Heart™, to the US market.”

Independently, QT Vascular will continue to develop and market its other products. This includes its differentiated drug coated percutaneous transluminal angioplasty balloon (Chocolate Touch®), which is currently enrolling patients in a 50 centre US IDE clinical trial. The Company also plans to develop, acquire and obtain rights to new products in new fields of use and to engage in research collaboration activities with large multinational partners.

The Company will convene an EGM to seek the approval of shareholders for the APOA. A circular containing further details on the transaction and enclosing the notice of EGM will be despatched by the Company to shareholders in due course.

The Company will continue to keep shareholders updated of any material developments as and when appropriate. In the meantime, shareholders and potential investors should exercise caution when trading in the shares of the Company.

*This press release is to be read in conjunction with the Company's announcement released on the SGXNet in relation to the APOA today.*

~~ End ~~

**ABOUT QT VASCULAR LTD. (SGX Stock code: 510)**

**QT Vascular Ltd.** together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC ("**TriReme Medical**"), based in Pleasanton, California.

For more information, please visit the company website at [www.qtvvascular.com](http://www.qtvvascular.com)

---

Issued on behalf of **QT VASCULAR LTD.** by:

---

**WATERBROOKS CONSULTANTS PTE LTD**

Tel: +65 6100 2228

***For media and analysts, please contact:***

Mr Wayne Koo (M): +65 9338 8166 wayne.koo@waterbrooks.com.sg

Ms Lynette Tan (M): +65 9687 2023 lynette@waterbrooks.com.sg

---

*Cautionary Note on Forward-Looking Statements*

*All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company does not undertake any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.*

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

*This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).*